IVX-411

IX-411

Vaccine description
Target	SARS-CoV-2
Vaccine type	Virus-like particles
Clinical data
Routes of administration	Intramuscular

IVX-411 is a COVID-19 candidate nanoparticle vaccine under development by Icosavax currently undergoing a Phase I/II clinical trial in Australia.[1] It was originally developed at the Institute of Protein Design (IPD) and the University of Washington School of Medicine, both based at the University of Washington.[2][3][4]

In 2022 results were released that the RDB antigen component of the vaccine was unstable, which resulted in reduced potency.[5]

References

1. "ANZCTR - Registration". anzctr.org.au. Retrieved 18 August 2021.
2. "Icosavax Initiates Phase 1/2 Trial of COVID-19 VLP Vaccine Candidate - Icosavax, Inc". investors.icosavax.com. Archived from the original on 30 October 2021. Retrieved 18 August 2021.
3. "Two nanoparticle vaccines enter clinical trials". Institute for Protein Design. 2 June 2021. Retrieved 18 August 2021.
4. Arunachalam PS, Walls AC, Golden N, Atyeo C, Fischinger S, Li C, et al. (June 2021). "Adjuvanting a subunit COVID-19 vaccine to induce protective immunity". Nature. 594 (7862): 253–258. Bibcode:2021Natur.594..253A. doi:10.1038/s41586-021-03530-2. PMID 33873199.
5. "Icosavax Announces Results from IVX-411 Drug Product Investigation and Outlines Additional Corporate Milestones". BioSpace. 28 July 2022.